ArticleNeurology(R) neuroimmunology & neuroinflammation2015

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Robert G Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.